SCHEMBL19642572

SCHEMBL19642572

COC(=O)C1CC(c2ccc(OC(F)F)cc2)=NN(c2cccc(F)c2)C1=O

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.41
ACSS2 Q9NR19 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
CRHBP P24387 1/20 0.39
CRHR2 Q13324 1/20 0.39
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
CACNA1H O95180 2/20 0.37
MAOB P27338 2/20 0.37
CSNK1E P49674 1/20 0.36
P2RX7 Q99572 1/20 0.36
PTGS2 P35354 1/20 0.36
MAOA P21397 1/20 0.35
ALDH1A1 P00352 1/20 0.35
PKM P14618 1/20 0.35
PDE5A O76074 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30187450 1.00 KDM4E (0.41) KDM4EACSS2MEN1KMT2ACRHBP
SCHEMBL30187464 0.90 KDM4E (0.48) KDM4EMEN1KMT2APDE4APDE4B
SCHEMBL19642610 0.90 KDM4E (0.48) KDM4EMEN1KMT2APDE4APDE4B
SCHEMBL28299533 0.89 KDM4E (0.41) KDM4EACSS2MEN1KMT2ACRHBP
SCHEMBL19642149 0.89 PDE4A (0.39) KDM4EMEN1KMT2APDE4APDE4B
SCHEMBL30187402 0.89 PDE4A (0.39) KDM4EMEN1KMT2APDE4APDE4B
SCHEMBL30187431 0.87 HPGD (0.44) KDM4EMEN1KMT2APDE4APDE4B
SCHEMBL19642564 0.87 HPGD (0.44) KDM4EMEN1KMT2APDE4APDE4B
SCHEMBL19643410 0.87 MEN1 (0.41) KDM4EMEN1KMT2APDE4APDE4B
SCHEMBL30187456 0.87 MEN1 (0.41) KDM4EMEN1KMT2APDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109863140-B 3-oxo-2, 6-diphenyl-2, 3-dihydropyridazine-4-carboxamide 拜耳医药股份有限公司 2023-02-21 CN disclosed
EP-3464248-B1 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES Bayer Pharma AG (DE) 2021-09-08 EP disclosed
EP-3464248-B1 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES Bayer Pharma AG (DE) 2021-09-08 EP disclosed
US-11040035-B2 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2021-06-22 US disclosed
US-11040035-B2 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2021-06-22 US disclosed
US-20200237757-A1 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-07-30 US disclosed
US-20200237757-A1 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-07-30 US disclosed
EP-3464248-A1 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES Bayer Pharma Aktiengesellschaft (DE) 2019-04-10 EP disclosed
WO-2017202816-A1 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-11-30 WO disclosed
WO-2017202816-A1 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11040035-B2 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides AHR, HRH2, HRH4 KDM4E 779/4885ACSS2 1459/4885MEN1 4479/4885
US-20200237757-A1 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES AHR, HRH2, HRH4 KDM4E 779/4885ACSS2 1459/4885MEN1 4479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.